Physician profile
David J Cage
NPI 1376542449
$3,313.62
in general payments reported to CMS, 2019-2025
22 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $305 · 2021: $547 · 2022: $489 · 2023: $348 · 2024: $505 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $455.44 | 2019-2025 | Total30, Tryptyr, Precision7 |
| Johnson & Johnson Vision Care, INC. | $412.88 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $397.56 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $354.66 | 2022-2025 | Infuse, Biotrue One Day, Biotrue |
| Sun Pharmaceutical Industries INC. | $326.35 | 2019-2025 | Cequa |
| Abb Con-Cise Optical Group LLC | $250.53 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Eyevance Pharmaceuticals LLC | $159.24 | 2019-2022 | |
| Oyster Point Pharma, INC. | $134.94 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $114.22 | 2021-2023 | Oxervate |
| Biotissue Holdings INC. | $93.21 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $88.40 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $85.78 | 2019 | |
| Allergan, INC. | $75.36 | 2019-2021 | |
| New World Medical,INC. | $74.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $63.97 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.31 | 2024 | Tepezza |
| Thea Pharma INC. | $48.59 | 2024-2025 | Iyuzeh |
| Coopervision INC. | $31.08 | 2025 | Myday Contact Lens |
| Visioneering Technologies, INC. | $31.04 | 2019 | |
| Harrow Eye, LLC | $21.80 | 2025 | Vevye |
| Abbvie INC. | $21.76 | 2022 | |
| Kala Pharmaceuticals, INC. | $19.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.